Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens

JAMA Oncology - Tập 8 Số 9 - Trang 1340 - 2022
Elias Jabbour1, Fadi G. Haddad1, Nicholas J. Short1, Hagop M. Kantarjian1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

Tóm tắt

ImportanceWith the advent of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs), Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now a relatively favorable-risk acute leukemia. In this review, we discuss the current evidence for frontline therapies of Ph-positive ALL, the major principles that guide therapy, and the progress with chemotherapy-free regimens.ObservationsIncorporating TKIs into the chemotherapy regimens of patients with newly diagnosed Ph-positive ALL has led to improved remission rates, higher probability of reaching allogeneic stem cell transplantation (SCT), and longer survival compared with chemotherapy alone. Early achievement of a complete molecular remission (CMR) is an important end point in Ph-positive ALL and identifies patients who have excellent long-term survival and may not need allogeneic SCT. Second-generation TKIs combined with intensive or low-intensity chemotherapy resulted in higher CMR rates compared with imatinib-based regimens. This translated into better outcomes, with less reliance on allogeneic SCT. To further improve the outcomes, the potent third-generation TKI ponatinib was added to chemotherapy. The combination of hyper-CVAD and ponatinib resulted in an overall CMR rate of 84% and a 5-year survival rate of 73% and 86% among patients who did and did not undergo allogeneic SCT, respectively, suggesting that allogeneic SCT may not be needed with this regimen. The recent chemotherapy-free combination of dasatinib and blinatumomab was safe and effective in patients with newly diagnosed Ph-positive ALL and resulted in an estimated 3-year OS rate of 80%; 50% of patients underwent allogeneic SCT. The chemotherapy-free regimen of ponatinib and blinatumomab resulted in a CMR rate of 86% and a 2-year survival rate of 93%, with no relapses or leukemia-related deaths, and with only 1 patient proceeding to allogeneic SCT.Conclusions and RelevanceThe promising results obtained with the chemotherapy-free regimens of blinatumomab plus TKIs question the role of allogeneic SCT in first remission. Patients with Ph-positive ALL who achieve early and deep molecular responses have excellent long-term outcomes and may not benefit from allogeneic SCT.

Từ khóa


Tài liệu tham khảo

Short, 2021, Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms., Leukemia, 35, 3044, 10.1038/s41375-021-01277-3

Jabbour, 2018, Progress and innovations in the management of adult acute lymphoblastic leukemia., JAMA Oncol, 4, 1413, 10.1001/jamaoncol.2018.1915

Samra, 2020, Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions., J Hematol Oncol, 13, 70, 10.1186/s13045-020-00905-2

Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia., N Engl J Med, 376, 836, 10.1056/NEJMoa1609783

Kantarjian, 2016, Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia., N Engl J Med, 375, 740, 10.1056/NEJMoa1509277

Martinelli, 2021, Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study., Eur J Cancer, 146, 107, 10.1016/j.ejca.2020.12.022

Stock, 2021, Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia., Cancer, 127, 905, 10.1002/cncr.v127.6

Thomas, 2008, Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL)., Blood, 112, 2931, 10.1182/blood.V112.11.2931.2931

Thomas, 2004, Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate., Blood, 103, 4396, 10.1182/blood-2003-08-2958

Thomas, 2006, Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)., Blood, 108, 284, 10.1182/blood.V108.11.284.284

Daver, 2015, Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Haematologica, 100, 653, 10.3324/haematol.2014.118588

Lee, 2005, Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia., Leukemia, 19, 1509, 10.1038/sj.leu.2403886

Yanada, 2006, High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group., J Clin Oncol, 24, 460, 10.1200/JCO.2005.03.2177

Bassan, 2010, Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00., J Clin Oncol, 28, 3644, 10.1200/JCO.2010.28.1287

Fielding, 2014, UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia., Blood, 123, 843, 10.1182/blood-2013-09-529008

de Labarthe, 2007, Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study., Blood, 109, 1408, 10.1182/blood-2006-03-011908

Tanguy-Schmidt, 2013, Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study., Biol Blood Marrow Transplant, 19, 150, 10.1016/j.bbmt.2012.08.021

Lim, 2015, Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia., Am J Hematol, 90, 1013, 10.1002/ajh.24137

Chalandon, 2015, Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia., Blood, 125, 3711, 10.1182/blood-2015-02-627935

Vignetti, 2007, Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol., Blood, 109, 3676, 10.1182/blood-2006-10-052746

Ravandi, 2015, Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Cancer, 121, 4158, 10.1002/cncr.29646

Ravandi, 2016, US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL., Blood Adv, 1, 250, 10.1182/bloodadvances.2016001495

Foà, 2011, Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Blood, 118, 6521, 10.1182/blood-2011-05-351403

Rousselot, 2016, Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL., Blood, 128, 774, 10.1182/blood-2016-02-700153

Chiaretti, 2015, Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients: updated results and refined genetic-based prognostic stratification., Blood, 126, 81, 10.1182/blood.V126.23.81.81

Kim, 2015, Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia., Blood, 126, 746, 10.1182/blood-2015-03-636548

Liu, 2019, Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up., Ann Hematol, 98, 633, 10.1007/s00277-019-03594-1

Ottmann, 2018, Nilotinib (Tasigna®) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02)., Blood, 132, 31, 10.1182/blood-2018-99-114552

Rousselot, 2021, The omission of high-dose cytarabine during consolidation therapy of Ph-positive ALL patients treated with nilotinib and low-intensity chemotherapy results in an increased risk of relapses despite non-inferior levels of late BCR-ABL1 mrd response: first results of the randomized Graaph-2014 study., Blood, 138, 512, 10.1182/blood-2021-148843

Short, 2019, Long-term safety and efficacy of hyper-CVAD plus ponatinib as frontline therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia., Blood, 134, 283, 10.1182/blood-2019-125146

Ribera, 2021, Ponatinib and chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of PONALFIL clinical trial., Blood, 138, 1230, 10.1182/blood-2021-148310

Martinelli, 2022, INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia., Blood Adv, 6, 1742, 10.1182/bloodadvances.2021004821

Ottmann, 2007, Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study., Blood, 110, 2309, 10.1182/blood-2007-02-073528

Short, 2017, Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?, Best Pract Res Clin Haematol, 30, 193, 10.1016/j.beha.2017.05.001

Kantarjian, 2021, Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis., Leukemia, 35, 440, 10.1038/s41375-020-01111-2

Jabbour, 2014, Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)., Blood, 123, 494, 10.1182/blood-2013-06-511592

Ravandi, 2010, First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia., Blood, 116, 2070, 10.1182/blood-2009-12-261586

Chiaretti, 2021, A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol., Haematologica, 106, 1828, 10.3324/haematol.2020.260935

Shen, 2020, Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial., JAMA Oncol, 6, 358, 10.1001/jamaoncol.2019.5868

Gong, 2021, A higher dose of dasatinib may increase the possibility of crossing the blood-brain barrier in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Clin Ther, 43, 1265, 10.1016/j.clinthera.2021.05.009

O’Hare, 2009, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance., Cancer Cell, 16, 401, 10.1016/j.ccr.2009.09.028

Jabbour, 2018, Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study., Lancet Haematol, 5, e618, 10.1016/S2352-3026(18)30176-5

Patel, 2017, Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial., Leukemia, 31, 58, 10.1038/leu.2016.219

Cortes, 2018, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial., Blood, 132, 393, 10.1182/blood-2016-09-739086

Cortes, 2021, Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial., Blood, 138, 2042, 10.1182/blood.2021012082

Jabbour, 2015, Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study., Lancet Oncol, 16, 1547, 10.1016/S1470-2045(15)00207-7

Sasaki, 2016, Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis., Cancer, 122, 3650, 10.1002/cncr.v122.23

Jabbour, 2018, Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia., Clin Lymphoma Myeloma Leuk, 18, 257, 10.1016/j.clml.2018.02.010

Jabbour, 2021, ALL-132: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): PhALLCON study., Clin Lymphoma Myeloma Leuk, 21, S269, 10.1016/S2152-2650(21)01653-0

Assi, 2017, Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia., Clin Lymphoma Myeloma Leuk, 17, 897, 10.1016/j.clml.2017.08.101

McCloskey, 2019, Blinatumomab in combination with tyrosine kinase inhibitors safely and effectively induces rapid, deep, and durable molecular responses in relapsed and refractory Philadelphia positive acute leukemias., Blood, 134, 3812, 10.1182/blood-2019-131838

Couturier, 2021, Blinatumomab?+?ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults., Leuk Lymphoma, 62, 620, 10.1080/10428194.2020.1844198

Foà, 2020, Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults., N Engl J Med, 383, 1613, 10.1056/NEJMoa2016272

Chiaretti, 2021, Updated results of the GIMEMA LAL2116 D-ALBA trial for newly diagnosed adults with Ph+ ALL., HemaSphere, 5

Short, 2021, Updated results of a phase II study of ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Blood, 138, 2298, 10.1182/blood-2021-153795

Leonard, 2021, Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL., Blood, 137, 939, 10.1182/blood.2020005655

Puzzolo, 2021, Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab., Blood, 138, 2290, 10.1182/blood.2021011822

Iacobucci, 2011, CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients., Clin Cancer Res, 17, 7413, 10.1158/1078-0432.CCR-11-1227

DeBoer, 2016, Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665., Leuk Lymphoma, 57, 2298, 10.3109/10428194.2016.1144881

Li, 2018, Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients., Leuk Lymphoma, 59, 1890, 10.1080/10428194.2017.1406933

Sasaki, 2022, Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib., Leukemia, 36, 1253, 10.1038/s41375-021-01496-8

Slayton, 2018, Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622., J Clin Oncol, 36, 2306, 10.1200/JCO.2017.76.7228

Paul, 2022, Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia., Am J Hematol, 10.1002/ajh.26622

Short, 2016, Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia., Blood, 128, 504, 10.1182/blood-2016-03-707562

Sasaki, 2021, Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors., Cancer, 127, 2648, 10.1002/cncr.v127.15

Cazzaniga, 2018, Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies., Haematologica, 103, 107, 10.3324/haematol.2017.176917

Hovorkova, 2017, Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology., Blood, 129, 2771, 10.1182/blood-2016-11-749978

Zaliova, 2009, Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring., Leukemia, 23, 944, 10.1038/leu.2008.386

Haddad, 2022, Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors., Am J Hematol, 10.1002/ajh.v97.7

Chalandon, 2018

Thông tin
Thông tin xuất bản

JAMA Oncology

Tập 8 Số 9

1340

Thông tin tác giả